Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/22
Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery SystemBusiness Wire • 09/20/22
Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 DiabetesBusiness Wire • 08/22/22
Insulet Corporation (PODD) CEO Jim Hollingshead on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)Business Wire • 08/04/22
Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery SystemBusiness Wire • 08/01/22
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 YearsBusiness Wire • 06/03/22
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock ConferenceBusiness Wire • 06/02/22
Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in MalaysiaBusiness Wire • 06/01/22
DexCom stock leads S&P 500's premarket gainers after denying merger talks, and Insulet stock dropsMarket Watch • 05/31/22
Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22